H1N1(新型インフルエンザA)ワクチンの世界市場2016-2020

◆英語タイトル:Global H1N1 Vaccines Market 2016-2020
◆商品コード:IRTNTR9538
◆発行会社(調査会社):Technavio
◆発行日:2016年6月3日
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、H1N1(新型インフルエンザA)ワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、H1N1(新型インフルエンザA)ワクチンの世界市場規模及び予測、投与経路別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About the H1N1 Vaccines Market
The high level of maturity in the H1N1 vaccines market has renewed the push to develop quadrivalent vaccines that address areas of the market with unmet medical needs. Vaccines that prevent H1N1 have been a long-standing void in the treatment algorithm. Therefore, the introduction advanced vaccines in the next decade will likely alter the global H1N1 vaccines market landscape. Sanofi, AstraZeneca, and VaxInnate have also invested in quadrivalent vaccines, such as Sanofi’s VaxiGrip, VaxInnate’s VAX2012Q, and AstraZeneca’s MEDI-550 vaccine, which will impact the US and Europe markets during the forecast period. Other areas of opportunity for novel entrants include vaccines with improved immune response and immunogenic infant vaccines.

Technavio’s analysts forecast the global H1N1 vaccines market to grow at a CAGR of 4.17% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global H1N1 vaccines market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent H1N1 infection. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global H1N1 Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Sanofi
• GSK
• Astra Zeneca
• CSL

[Other prominent vendors]
• Abbott
• Baxter International
• CEL-SCI
• Cipla
• Crucell
• Denka Seiken
• Green Cross
• Hualan Biological Engineering
• iBio
• Imunoloski Zavod
• Inovio Biomedical
• Lupin
• Medicago USA
• Merck
• Mitsubishi Tanabe Pharma
• Omnivest
• Panacea
• Pfizer
• Protein Sciences
• Serum Institute of India
• Sinovac Biotech
• Solvay
• Zhejiang Tianyuan Bio-pharmaceuticals
• Zydus Cadila

[Market driver]
• Global action plan for influenza vaccines
• For a full, detailed list, view our report

[Market challenge]
• Vaccine storage and handling issues
• For a full, detailed list, view our report

[Market trend]
• Improved understanding of immunology
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Causes of H1N1 diseases
• Signs and symptoms

PART 06: Regulatory scenario of vaccines

PART 07: WHO recommendations for H1N1 vaccines
• Key H1N1 virus vaccines for 2014-2015 season in US
• H1N1 virus vaccines approved in EU

PART 08: Reimbursement for influenza vaccines in US
• The US healthcare reform
• Reimbursement for influenza vaccines

PART 09: Reimbursement for influenza vaccines in other major countries
• UK
• Germany
• Spain
• Italy
• France
• Japan

PART 10: Market landscape
• Global human vaccines market
• Global H1N1 vaccines market
• Five forces analysis

PART 11: Market segmentation by ROA
• Intramuscular vaccines
• Intranasal vaccines
• Intradermal vaccines

PART 12: Geographical segmentation
• Global H1N1 vaccines market by geographical segmentation 2015-2020
• H1N1 vaccines market in Americas
• H1N1 vaccines market in EMEA
• H1N1 vaccines market in APAC

PART 13: Market drivers
• Global action plan for influenza vaccines
• Increase in R&D
• Inclusion in NIP
• Rise in awareness

PART 14: Impact of drivers

PART 15: Market challenges
• Antigenic drift and shift of H1N1v virus
• Vaccine storage and handling issues
• Stringent regulatory guidelines
• Emergence of local players

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Universal influenza vaccine
• Emergence of quadrivalent vaccines
• Increase in strategic alliances and M&A
• Improved understanding of immunology

PART 18: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Sanofi
• GSK
• AstraZeneca
• CSL
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for H1N1 vaccines
Exhibit 03: Pediatric influenza vaccine price list 2015
Exhibit 04: Adult influenza vaccine price list 2015
Exhibit 05: Requirements for a BLA submission
Exhibit 06: Different types of development necessary to reach the vaccine licensing stage
Exhibit 07: Typical vaccine development process (over a period of up to 15 years and at a cost of up to $1 billion)
Exhibit 08: Regulatory testing of licensed vaccines
Exhibit 09: Comparison of US healthcare system before and after reforms
Exhibit 10: Coding options for diagnosis of influenza vaccines
Exhibit 11: Medicare (Part B) current procedural terminology (CPT) codes for influenza vaccines
Exhibit 12: Top 10 pharmaceutical companies based on global vaccines market revenues 2015 ($ billions)
Exhibit 13: Global human vaccines market 2015-2020 ($ billions)
Exhibit 14: Market share of H1N1 vaccines markets in global human vaccines market 2015
Exhibit 15: Global H1N1 vaccines market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global H1N1 vaccines market segmentation by ROA
Exhibit 18: Global H1N1 vaccines market segmentation by ROA 2015
Exhibit 19: Global H1N1 vaccines market by geography 2015
Exhibit 20: Global H1N1 vaccines market by geography 2020
Exhibit 21: Global H1N1 vaccines market revenue by geography 2015-2020 ($ billions)
Exhibit 22: Percentage share of H1N1 vaccines market by geography 2015-2020
Exhibit 23: Global H1N1 vaccines market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 24: H1N1 vaccines market in Americas 2015-2020 ($ billions)
Exhibit 25: H1N1 vaccines market in EMEA 2015-2020 ($ millions)
Exhibit 26: H1N1 vaccines market in APAC 2015-2020 ($ millions)
Exhibit 27: A few pipeline molecules for H1N1 vaccines
Exhibit 28: Impact of drivers
Exhibit 29: A typical cold chain process
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Overview of major H1N1 vaccine-related acquisitions 2005-2012)
Exhibit 32: Market share analysis of global H1N1 vaccines market 2015
Exhibit 33: Sanofi: YoY revenue growth of influenza vaccines 2013-2015 ($ billions)
Exhibit 34: Sanofi: Geographic segmentation of influenza vaccines 2015
Exhibit 35: Sanofi: Key takeaways
Exhibit 36: GSK: YoY revenue and growth rate of Fluarix and FluLaval 2013-2015 ($ millions)
Exhibit 37: GSK: Geographical segmentation of Fluarix and FluLaval 2015
Exhibit 38: GSK: Key takeaways
Exhibit 39: AstraZeneca: YoY revenue and growth rate of Fluenz 2013-2015 ($ millions)
Exhibit 40: AstraZeneca: Geographical segmentation of Fluenz 2015 ($ millions)
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: CSL: YoY revenue and growth rate of influenza vaccines 2013-2015 ($ millions)
Exhibit 43: CSL: Key takeaways



【掲載企業】

Sanofi, GSK, Astra Zeneca, CSL, Abbott, Baxter International, CEL-SCI, Cipla, Crucell, Denka Seiken, Green Cross, Hualan Biological Engineering, iBio, Imunoloski Zavod, Inovio Biomedical, Lupin, Medicago USA, Merck, Mitsubishi Tanabe Pharma, Omnivest, Panacea, Pfizer, Protein Sciences, Serum Institute of India, Sinovac Biotech, Solvay, Zhejiang Tianyuan Bio-pharmaceuticals, Zydus Cadila.

【レポートのキーワード】

新型インフルエンザA、H1N1ワクチン、治療、A型インフルエンザウイルス

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[H1N1(新型インフルエンザA)ワクチンの世界市場2016-2020]販売に関する免責事項
★調査レポート[H1N1(新型インフルエンザA)ワクチンの世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆